Key result
Ezetimibe is linked to outsized LDL-C reductions in ketogenic diet-induced hypercholesterolemia.
Why the study?
Does ezetimibe improve LDL-C reduction in patients with ketogenic diet-induced hypercholesterolemia?
Observational (n=14)
Does ezetimibe improve LDL-C reduction in patients with ketogenic diet-induced hypercholesterolemia?
Captured external expert commentary on this paper, strongest first. Original sources are linked where available.
“This was not a minor laboratory fluctuation. The median LDL reduction exceeded 125 mg/dL. Even among patients taking ezetimibe without a statin, LDL fell by approximately 50%. That is a biological signal too large to dismiss.”
“Medicine has trained physicians to see high LDL and reflexively prescribe a statin, followed by an expensive PCSK9 drug when the statin fails, causes side effects, or does not produce a sufficient reduction. Our findings suggest that this script may target the wrong pathway in some patients. If the physiology is different, the treatment should be different.”
Ezetimibe may be particularly effective for lowering LDL-C in patients with ketogenic diet-induced hypercholesterolemia, possibly due to altered cholesterol absorption mechanisms.
Several case reports and a meta-analysis have documented significant increases in cholesterol levels among individuals following a ketogenic diet. However, the mechanistic drivers of this phenotype remain incompletely understood. Here, we describe a retrospective case series of 14 patients with ketogenic diet-induced hypercholesterolemia who experienced larger-than-expected LDL-C reductions after ezetimibe therapy. In a subset of participants with available genetic data, no biallelic sitosterolemia-associated variants were identified in the loci assessed. We hypothesize that chronically low insulin levels may alter hepatic cholesterol homeostasis through changes in ACAT2-mediated cholesterol esterification and in NPC1L1/ABCG5/G8-mediated cholesterol handling. The magnitude of LDL-C reduction achieved with ezetimibe in this cohort suggests that altered cholesterol absorption may contribute importantly to this phenotype. This hypothesis-generating framework offers a plausible mechanistic explanation and supports further prospective study of precision lipid management in ketogenic diet-induced hypercholesterolemia.
No takes yet. Share an insight, caveat, or question.
Gonzalez et al. (2026) conducted an observational in Ketogenic diet-induced hypercholesterolemia (n=14). Ezetimibe was evaluated on LDL-C reduction. In a retrospective case series of 14 patients, ezetimibe therapy resulted in larger-than-expected LDL-C reductions in those with ketogenic diet-induced hypercholesterolemia.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: